• Metabolic disease biotech Akero achieves key clinical trial win in liver disease NASH

    21 days ago - By MedCity News

    Akero Therapeutics' experimental NASH drug, efruxifermin, met the main and secondary goals of Phase 2b clinical trial. The biotech will still need to show that the drug's efficacy can hold up in a pivotal study, but the results so far are a positive sign for the NASH field, which has been marred by clinical trial failures.
    Read more ...